Feedback

Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank

Affiliation
Department of Nephrology ,Mianyang Central Hospital ,School of Medicine ,University of Electronic Science and Technology of China ,Mianyang ,China
Zhang, Xing-Yu;
Affiliation
Clinical Research Center ,Guangdong; Scientific Research Center ,The Seventh Affiliated Hospital ,Sun Yat-sen University ,Shenzhen ,China
He, Qiang-Sheng;
Affiliation
Department of Nephrology ,Mianyang 404 Hospital ,Mianyang ,China
Jing, Zhong;
Affiliation
Department of Information Engineering ,University of Lanzhou City ,Lanzhou ,China
He, Juan-Xia;
Affiliation
Clinical Research Center ,Guangdong; Scientific Research Center ,The Seventh Affiliated Hospital ,Sun Yat-sen University ,Shenzhen ,China
Yuan, Jin-Qiu;
Affiliation
Department of Nephrology ,Mianyang Central Hospital ,School of Medicine ,University of Electronic Science and Technology of China ,Mianyang ,China
Dai, Xiao-Yu

Background: Proton pump inhibitors (PPIs) are widely used and have been linked to kidney diseases. However, the role of PPI use in the development of chronic kidney disease (CKD) remains unclear. We undertook this study to examine the association between PPI use and the subsequent risk of CKD. Methods: This is a prospective analysis of 462,421 participants free of cancer diagnosis or chronic kidney disease from the United Kingdom Biobank. Self-reported PPI use was recorded using an electronic questionnaire and confirmed by a trained staff. Incident CKD was identified based on the medical history. Overlap propensity score weighting with the Cox model was used to calculate the effect of PPI use on CKD risk. The number needed to harm (NNH) was calculated at 5 and 10 years of follow-up. Results: We documented 7,031 cases of CKD over a median follow-up of 8.1 years. Overlap propensity score weighting analysis showed that regular PPI users had a 37% higher risk of CKD incident than non-users (HR 1.37, 95% CI 1.28–1.47). The association persisted across subgroup analyses, different types of PPIs, and several sensitivity analyses. Quantitative bias analysis indicated that the result was robust to unmeasured confounding (E-value 2.08, lower 95% CI 1.88). The NNH was 147.9 and 78.6 for 5 and 10 years of follow-up, respectively. A head-to-head comparison showed that PPI users had a 19% higher risk of CKD than H2RA users (HR 1.19, 95% CI 1.02–1.39). Conclusion: The regular use of PPI is associated with a higher risk of CKD. Healthcare providers should carefully weigh up the potential benefits against the risk in prescribing PPIs, particularly for patients requiring long-term treatment.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Zhang, He, Jing, He, Yuan and Dai.

Use and reproduction: